News & Events

July 2019

July 10, 2019 Fujifilm and Axcelead Drug Discovery Partners Begin Collaborating to Advance Drug Discovery Solutions Using iPSCs

To enhance the Process of Research and Development of Drug Candidates

Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners, Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived products that its U.S. subsidiary FUJIFILM Cellular Dynamics Inc. (FCDI) offers and Axcelead’s compound evaluation and analytical services, the companies will work towards developing new drug efficacy evaluation methods and toxicity testing to meet specific needs of clients.

July 1, 2019 Century Therapeutics Launches with $250M Financing for iPSC Allogeneic Cell Therapy Platform

Tokyo, June 1, 2019 ― FUJIFILM Corporation (President: Kenji Sukeno) will accelerate the development of next-generation cancer immunotherapeutic drug candidates by harnessing the self-renewal potential of allogenic induced pluripotent stem cells (iPSCs). FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human iPSCs and tissue-specific cells differentiated from iPSCs, and Versant Venture Management,…